Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SGMT vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMT Captures Overall Composite Edge (52.6 HOLD vs 43.9 HOLD), While CAMP Leads 3–2 on Growth & Valuation Pillars

SGMT Overall Winner 6-Pillar Tally: SGMT 2 – 3 CAMP (1 Tie) Matrix Metrics: SGMT 6 – 1 CAMP

As of Nov 17, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.6/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $9.78 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin).

  • Growth vs. Quality Trade-Off: SGMT earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.08β · 84% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SGMT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.5); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGMT vs CAMP
SGMT NASDAQ Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.78
-3.5% 1D
Market Cap $735.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.08β · 84% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 36.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 47.5 · SMA20: $10.17 · SMA50: $9.84
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.35β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (SGMT 2 – 3 CAMP)

Columns: Metric · SGMT · CAMP
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 26.6x
2. Growth & Scale CAMP
Revenue Growth (YoY) +0.0% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $5.3M
Market Cap $735.2M $238.5M
3. Profitability & Quality SGMT
Gross Margin N/A N/A
Operating Margin 0.0% -991.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.5% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$44M -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $109M Net Cash $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 81.6% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGMT (6) vs CAMP (1)
Institutional Metric SGMT CAMP Criterion Row Edge
Market Capitalization
Scale
$735.2M $238.5M Larger Scale SGMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
0.0% -991.8% Higher Margin SGMT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.5% -146.1% Higher ROE SGMT
52-Week Range Position
Momentum
76% ($4–$11) 23% ($3–$8) Stronger Trend SGMT
Beta / 30D Volatility
Risk Regime
2.08β · 84% Vol 1.35β · 94% Vol Lower Realized Risk SGMT
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite SGMT
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($109M Net Cash) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +17.06 pp
SGMT: +10.33% · CAMP: +27.39%
3M Horizon SGMT +6.37 pp
SGMT: -7.61% · CAMP: -13.98%
6M Horizon SGMT +53.07 pp
SGMT: +49.46% · CAMP: -3.61%
1Y Horizon SGMT +28.57 pp
SGMT: +26.13% · CAMP: -2.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGMT Revenue CAMP Revenue SGMT Op. Margin CAMP Op. Margin Margin Leader
FY2023 $0M $0M -1537.0% -14822.6% SGMT
FY2024 N/A $0M N/A -8142.3% CAMP
FY2025 N/A $0M N/A -1502.4% CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGMT BREAKOUT
141d in phase · OBV NEUTRAL
Current IV 81.6%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $735.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGMT vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.6/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $9.78 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin). Growth vs. Quality Trade-Off: SGMT earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.08β · 84% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SGMT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.5); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: SGMT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), SGMT cumulative revenue shifted N/A while CAMP shifted N/A. In operating R&D and SG&A reinvestment, SGMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

CAMP screens cheaper on headline valuation multiples. SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMT (-29.5% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SGMT carries 81.6% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.08β · 84% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.